Pacira Pharmaceuticals buy Piper Sandler
Start price
03.07.24
/
50%
€20.40
Target price
03.07.25
€38.93
Performance (%)
-5.39%
End price
04.07.25
€19.30
Summary
This prediction ended on 04.07.25 with a price of €19.30. With a performance of -5.39%, the BUY prediction by Piper_Sandler finished with a loss. Piper_Sandler has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Pacira Pharmaceuticals | 3.571% | 3.571% | 25.405% |
| iShares Core DAX® | 1,01 % | 2,70 % | 4,36 % |
| iShares Nasdaq 100 | -6,47 % | -8,77 % | 18,00 % |
| iShares Nikkei 225® | -6,52 % | -12,58 % | 40,91 % |
| iShares S&P 500 | -2,72 % | -1,75 % | 16,97 % |
Comments by Piper_Sandler for this prediction
In the thread Pacira Pharmaceuticals diskutieren
Pacira BioSciences, Inc. (NASDAQ: PCRX) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $42.00 price target on the stock.
Ratings data for PCRX provided by MarketBeat
In the thread Trading Pacira Pharmaceuticals
Die von Piper_Sandler gewählte maximale Laufzeit wurde überschritten